Cargando…
Synthetic lethality: emerging targets and opportunities in melanoma
Great progress has been made in the treatment of melanoma through use of targeted therapies and immunotherapy. One approach that has not been fully explored is synthetic lethality, which exploits somatically acquired changes, usually driver mutations, to specifically kill tumour cells. We outline th...
Autores principales: | Thompson, Nicola, Adams, David J., Ranzani, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396340/ https://www.ncbi.nlm.nih.gov/pubmed/28097822 http://dx.doi.org/10.1111/pcmr.12573 |
Ejemplares similares
-
Synthetic Lethality Targeting Polθ
por: Drzewiecka, Małgorzata, et al.
Publicado: (2022) -
CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
por: Houles, Thibault, et al.
Publicado: (2022) -
Emerging Opportunities for Synthetic Biology in Agriculture
por: Goold, Hugh Douglas, et al.
Publicado: (2018) -
Approaches to Identifying Synthetic Lethal Interactions in Cancer
por: Thompson, Jordan M., et al.
Publicado: (2015) -
DNA repair and synthetic lethality
por: Guo, Gong-she, et al.
Publicado: (2011)